Powering Superior Immune Synapses | Third Arc Bio Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases
Third Arc debuts with $165M and trio of former J J execs at the helm Third Arc has a solid tumour “synergy” technology for cancer drug discovery, and for autoimmune diseases, it has an inflammatory and immunology platform that aims to regulate the immune system at a tissue-specific level Tuesday’s funding will move multiple candidates into the clinic in early 2025